Tuesday, April 10, 2012
RedHill Biopharma Ltd., of Tel Aviv, Israel, said initial analysis of a pharmacokinetic study comparing its version of odansetron with Zofran (odansetron, GlaxoSmithKline plc) showed the trial met its objective of establishing bioequivalence. Assuming the final clinical study report supports the preliminary findings, RedHill said it will consider filing for U.S. marketing approval.
Note: our contact information has changed
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
© 2013 Thomson Reuters. Reproduction, reposting content is strictly prohibited.
Sign up for Perspectives FREE e-mail newsletter